Boehringer Ingelheim Presents Innovative Cancer Treatments at ASCO 2025 At ASCO 2025, Boehringer Ingelheim showcases their cutting-edge cancer therapies, emphasizing breakthroughs in HER2-mutant NSCLC and neuroendocrine carcinomas.

Boehringer Ingelheim Presents Innovative Cancer Treatments at ASCO 2025 #United_States #Chicago #Boehringer_Ingelheim #Zongertinib #Obrixtamig